ADEOLA AJAYI, EKITI
After two vaccine have successfully undergone human trial. The good news have been revealed out that A COVID-19 vaccine developed by the biotechnology company, Morderna, has shown promise in key early trial, producing immune responses in all persons it was tested on.
On the safety of the vaccine, they said “no serious adverse events were noted, and no pre-specified trial halting rules were met.”
They added that “local adverse events, when present, were nearly all mild or moderate, and pain at the injection site was common.
“Across both vaccinations, solicited systemic and local adverse events that occurred in more than half the participants included fatigue, chills, headache, myalgia, and pain at the injection site.”
The researchers said the safety and immunogenicity findings support advancement of the mRNA-1273 vaccine to later-stage clinical trials.
“Of the three doses evaluated, the 100-μg dose elicits high neutralization responses and Th1-skewed CD4 T cell responses, coupled with a reactogenicity profile that is more favourable than that of the higher dose.
“A phase 2 trial of mRNA-1273 in 600 healthy adults, evaluating doses of 50 μg and 100 μg, is ongoing.
“A large phase 3 efficacy trial, expected to evaluate a 100-μg dose, is anticipated to begin during the summer of 2020,” they explained.